Myelodysplastic, myeloproliferative, and other hematopoietic neoplasms

• 2001Imatinib approved (FDA)
• 2004Azacitidine approved (FDA)
• 2006Decitabine approved (FDA)
• 2011Ruxolitinib approved (FDA)
• 2019Ropeginterferon alfa-2b approved (FDA)
• 2022Pacritinib approved (FDA)
• 2023Momelotinib approved (FDA)
• 2023Omidubicel non-cultured fraction approved (FDA)
• 2023Omidubicel approved (FDA)

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

These blood cancers are now treated with disease-modifying therapies that improve survival and control symptoms, though they are not typically curative. Over the past two decades, outcomes have improved substantially for many patients. The 2001 approval of imatinib marked a turning point, turning chronic myeloid leukemia into a manageable chronic condition. Later drugs, including azacitidine, decitabine, ruxolitinib, and ropeginterferon alfa-2b, expanded options for related disorders. Allogeneic stem cell transplant can cure some patients, but it is not standard for most. Overall, the trajectory is one of steady progress, with more patients living longer and better lives.

Can these blood cancers be cured?

For some patients, an allogeneic stem cell transplant can be curative, but it is not suitable or standard for everyone. Most treatments aim to control the disease, improve symptoms, and extend survival.

How has treatment changed in recent years?

Targeted therapies like imatinib, approved in 2001, transformed chronic myeloid leukemia from a rapidly fatal disease into a manageable condition. Subsequent drugs have broadened effective treatment for related blood cancers.

What is the goal of treatment if not cure?

The goal is disease modification: reducing symptoms, preventing complications, and prolonging life. Many patients live for years with good quality of life on ongoing therapy.

Are new treatments being developed?

Yes. Over 400 clinical trials have started in the last five years, including more than 30 phase 3 studies, so the pipeline for new therapies remains active and promising.